Trial · NCT04740905
Adverse events380
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 380
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | COVID-19 | Infections and infestations | Arm A: Faricimab Q4W (Part 1) | 10 | 276 | 10 |
| other | COVID-19 | Infections and infestations | Arm B: Aflibercept Q4W (Part 1) | 16 | 274 | 16 |
| other | COVID-19 | Infections and infestations | Arm A: Faricimab Q4W to Faricimab PTI (Part 2) | 32 | 270 | 32 |
| other | COVID-19 | Infections and infestations | Arm B: Aflibercept Q4W to Faricimab PTI (Part 2) | 25 | 267 | 25 |
| other | Hypertension | Vascular disorders | Arm A: Faricimab Q4W (Part 1) | 20 | 276 | 21 |
| other | Hypertension | Vascular disorders | Arm B: Aflibercept Q4W (Part 1) | 7 | 274 | 7 |
| other | Hypertension | Vascular disorders | Arm A: Faricimab Q4W to Faricimab PTI (Part 2) | 14 | 270 | 14 |
| other | Hypertension | Vascular disorders | Arm B: Aflibercept Q4W to Faricimab PTI (Part 2) | 8 | 267 | 8 |
| other | Conjunctival haemorrhage | Eye disorders | Arm A: Faricimab Q4W (Part 1) | 8 | 276 | 9 |
| other | Conjunctival haemorrhage | Eye disorders | Arm B: Aflibercept Q4W (Part 1) | 10 | 274 | 11 |
| other | Conjunctival haemorrhage | Eye disorders | Arm A: Faricimab Q4W to Faricimab PTI (Part 2) | 11 | 270 | 11 |
| other | Conjunctival haemorrhage | Eye disorders | Arm B: Aflibercept Q4W to Faricimab PTI (Part 2) | 10 | 267 | 11 |
| other | Dry eye | Eye disorders | Arm A: Faricimab Q4W (Part 1) | 5 | 276 | 5 |
| other | Dry eye | Eye disorders | Arm B: Aflibercept Q4W (Part 1) | 9 | 274 | 9 |
| other | Dry eye | Eye disorders | Arm A: Faricimab Q4W to Faricimab PTI (Part 2) | 4 | 270 | 5 |
| other | Dry eye | Eye disorders | Arm B: Aflibercept Q4W to Faricimab PTI (Part 2) | 4 | 267 | 4 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Arm A: Faricimab Q4W (Part 1) | 2 | 276 | 2 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Arm B: Aflibercept Q4W (Part 1) | 10 | 274 | 10 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Arm A: Faricimab Q4W to Faricimab PTI (Part 2) | 5 | 270 | 6 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Arm B: Aflibercept Q4W to Faricimab PTI (Part 2) | 4 | 267 | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04740905/events